![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Pharma Equity Group
0,296 DKK +9,63%HC Andersen Capital saa maksun yhtiöltä Pharma Equity Group DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.
12 sijoittajaa seuraa yhtiötä
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Liikevaihto
-
EBIT %
-
P/E -luku
-
Osinkotuotto %
-
Tavoitehinta
-
Suositus
-
Päivitetty
-
NASDAQ Copenhagen
PEG
Päivän matalin / päivän korkein hinta
0,259 / 0,299
DKK
Markkina-arvo
302,8 milj. DKK
Vaihto
691,44 t. DKK
Vaihtomäärä, kappaletta
2,5 milj.
Viimeisimmät analyysit
Laaja raportti
Inderesin laaja raportti on syvällisin asiakasyhtiöstämme tehty tutkimus.
Uusin laaja raportti on julkaistu
Lue raporttiAnalyst
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
Claus Thestrup
CEO, Sweden
Viimeisimmät videot
Pörssikalenteri
Osavuosikatsaus
16.08.2024
Osavuosikatsaus
15.11.2024
NäytäKaikki sisältötyypit
![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
![Life Science seminar 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
Life Science seminar 2024
Results of extraordinary general meeting in Pharma Equity Group A/S
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
![Pharma Equity Group: Investors appreciate eventful, and mostly positive, 1. quarter 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/e63e4a03-8498-4f91-be79-24be09bcc666.png)
Pharma Equity Group: Investors appreciate eventful, and mostly positive, 1. quarter 2024
The Board of Director's decision to issue convertible loans
Consolidated interim report 1 January – 31 March 2024
Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S
Notice convening the extraordinary general meeting of Pharma Equity Group A/S
![Pharma Equity Group (One-pager): Continues to move forward but the shares continues to slide](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/e63e4a03-8498-4f91-be79-24be09bcc666.png)
Pharma Equity Group (One-pager): Continues to move forward but the shares continues to slide
Major shareholder announcement - Pharma Equity Group A/S
Passing of the General Meeting of Pharma Equity Group A/S
The Board of Director's decision to issue convertible loans
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.
Notice convening the annual general meeting in Pharma Equity Group A/S
Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009
Completion of subscription of convertible loans
Correction: Pharma Equity Group A/S - Annual Report 2023
Pharma Equity Group A/S - Annual Report 2023
![HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/06aef4ac-f94b-407d-ac4d-dffe67b0f7a5.png)